All In Biotech

NDA 022057 · Ferring

Endometrin

Progesterone · Vaginal · Progesterone

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jun 21, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

897

206 Phase 3, 84 recruiting

FAERS reports

20,274

11,005 serious, 452 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

ENDOMETRIN ® is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ENDOMETRIN is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.

Mechanism: Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ENDOMETRIN · PROGESTERONE 100MG · INSERT, VAGINAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Progesterone" as an intervention, any sponsor and status, largest first.

All 897 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache1,856
  • off label use1,663
  • drug ineffective1,652
  • fatigue1,574
  • nausea1,315
  • pain1,294
  • exposure during pregnancy903
  • foetal exposure during pregnancy903
  • rash901
  • dizziness820
  • maternal exposure during pregnancy793
  • hypersensitivity780

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004136
2005154
2006140
2007114
2008169
2009235
2010271
2011243
2012388
2013366
2014461
2015822
20161,211
2017984
20181,063
20191,243
20201,286
20211,265
20221,446
20231,603
20241,999
20252,194
20262,481

Recalls

1 FDA enforcement reports for this application.

  • Sep 19, 2013 · Class III · Terminated

    Discoloration; due to prolonged heat exposure.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Endometrin (Progesterone, Micronized)

2024 spending

$9K

Beneficiaries

n/a

19 claims

Per beneficiary

n/a

$13.13 per unit

View as table
YearSpending
2020$10,252
2021$21,299
2022$12,878
2023$8,161
2024$9,215

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,179 on PubMed

Sponsor: Ferring

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.